CpG ODN-induced matrix metalloproteinase-13 expression is mediated via activation of the ERK and NF-κB signalling pathways in odontoblast cells

Int Endod J. 2013 Jul;46(7):666-74. doi: 10.1111/iej.12043. Epub 2013 Jan 21.

Abstract

Aim: To investigate the effects of CpG ODN (CpG oligodeoxynucleotides) to model the action of bacterial challenge on pulpal matrix metalloproteinase-13 (MMP-13) expression and elucidate the associated intracellular signalling pathways.

Methodology: Real-time PCR was used to detect the effects of CpG ODN on MMP-13 mRNA expression levels in a murine odontoblast-lineage cell line (OLCs). The possible involvement of TLR9/MyD88, NF-κB or MAPK pathways involved in the CpG ODN-induced MMP-13 expression was examined by real-time PCR, transient transfection, luciferase activity assay and ELISA. Western blotting was performed to assay the phosphorylation of ERK at a range of time points.

Results: MMP-13 was constitutively expressed in OLCs, and their exposure to CpG ODN significantly increased MMP-13 expression. Pre-treatment of OLCs with the inhibitory peptide MyD88, or chloroquine, attenuated the CpG ODN-induced expression of MMP-13. Treatment of the OLCs with CpG ODN increased NF-κB-luciferase activity. This activity was decreased by the over-expression of a nondegrading mutant of IκBα (IκBαSR), although enhanced by the over-expression of NF-κB p65. MMP-13 expression induced by CpG ODN was markedly suppressed by NF-κB inhibitors (pyrrolidine dithiocarbamate, PDTC), IκBα phosphorylation inhibitors (Bay 117082) or IκB protease inhibitor (L-1-tosylamido-2-phenylethyl chloromethyl ketone, TPCK). The inhibitor of ERK1/2, U0126, but not inhibitors of p38 MAPK and JNK, SB203580 and SP600125, decreased CpG ODN-mediated MMP-13 expression.

Conclusion: The CpG ODN-induced MMP-13 expression in OLCs is mediated through TLR9, NF-κB and the ERK pathway indicating that potentially the recognition of CpG ODN by TLR9 on odontoblasts may regulate the remodelling of injured dental pulp and hard tissues by inducing MMP-13 expression.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anthracenes / pharmacology
  • Cell Line
  • Chloroquine / pharmacology
  • CpG Islands*
  • Dental Pulp / drug effects
  • Dental Pulp / enzymology*
  • Extracellular Signal-Regulated MAP Kinases / drug effects
  • I-kappa B Proteins / pharmacology
  • Imidazoles / pharmacology
  • MAP Kinase Signaling System / drug effects
  • Matrix Metalloproteinase 13 / drug effects*
  • Mice
  • Mitogen-Activated Protein Kinases / antagonists & inhibitors
  • Myeloid Differentiation Factor 88 / pharmacology
  • NF-kappa B / antagonists & inhibitors
  • NF-kappa B / drug effects
  • Nitriles / pharmacology
  • Odontoblasts / drug effects
  • Odontoblasts / enzymology
  • Oligodeoxyribonucleotides / pharmacology*
  • Phosphorylation
  • Pyridines / pharmacology
  • Pyrrolidines / pharmacology
  • Real-Time Polymerase Chain Reaction
  • Signal Transduction / drug effects
  • Sulfones / pharmacology
  • Thiocarbamates / pharmacology
  • Toll-Like Receptor 9 / drug effects
  • Tosylphenylalanyl Chloromethyl Ketone / pharmacology
  • Transcription Factor RelA / pharmacology

Substances

  • 3-(4-methylphenylsulfonyl)-2-propenenitrile
  • Anthracenes
  • CPG-oligonucleotide
  • I kappa B beta protein
  • I-kappa B Proteins
  • Imidazoles
  • Myd88 protein, mouse
  • Myeloid Differentiation Factor 88
  • NF-kappa B
  • Nitriles
  • Oligodeoxyribonucleotides
  • Pyridines
  • Pyrrolidines
  • Rela protein, mouse
  • Sulfones
  • Thiocarbamates
  • Tlr9 protein, mouse
  • Toll-Like Receptor 9
  • Transcription Factor RelA
  • pyrazolanthrone
  • pyrrolidine dithiocarbamic acid
  • Tosylphenylalanyl Chloromethyl Ketone
  • Chloroquine
  • Extracellular Signal-Regulated MAP Kinases
  • Mitogen-Activated Protein Kinases
  • Matrix Metalloproteinase 13
  • Mmp13 protein, mouse
  • SB 203580